$2B deal signed to develop gene-silencing drugs

08:05 EDT 26 Mar 2020 | SmartBrief

AstraZeneca has partnered with UK-based Silence Therapeutics to develop drugs targeting the liver using the latter's small in -More

Original Article: $2B deal signed to develop gene-silencing drugs


More From BioPortfolio on "$2B deal signed to develop gene-silencing drugs"

Quick Search

Relevant Topics

AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...